Core Insights - Medtronic reported FY26 Q3 revenue of $9.02 billion, reflecting an 8.7% year-over-year growth, with cardiovascular revenue at $3.46 billion (nearly 14% growth) and diabetes revenue at $796 million (nearly 15% growth) [1] Group 1: Hugo Robotic Surgery System - The first U.S. procedure using Medtronic's Hugo robotic surgery system was completed at the Cleveland Clinic, following FDA clearance for the platform [2][4] - CEO Geoff Martha indicated that while the initial cases were completed, the number of Hugo installations and procedures was not specified, but growth is occurring "pretty fast" [3] - Medtronic aims to capture market share from Intuitive Surgical in the soft tissue robotics sector, with both Medtronic and Johnson & Johnson being the largest competitors due to their resources and existing surgical businesses [5] Group 2: Market Reception and Challenges - The reception for the Hugo system in the U.S. market has been positive, with orders being received, according to CEO Geoff Martha [4] - Analysts express skepticism regarding Hugo's ability to compete with Intuitive Surgical, citing its limited urology indication and the advancements made by Intuitive with its da Vinci robot [6]